PolyPid
Logotype for PolyPid Ltd

PolyPid (PYPD) investor relations material

PolyPid Q4 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for PolyPid Ltd
Q4 2025 earnings summary11 Feb, 2026

Executive summary

  • Completed SHIELD II Phase III trial with D-PLEX100 meeting all primary and key secondary endpoints, showing significant reduction in surgical site infections.

  • Advanced D-PLEX100 to final regulatory preparation, with positive FDA pre-NDA feedback supporting a rolling NDA submission expected by end of Q1 2026.

  • Progressed U.S. commercial partnership discussions to advanced stages, reflecting strong clinical data and market need.

  • Introduced Kynatrix technology, expanding drug delivery capabilities into new therapeutic areas, including metabolic diseases.

  • Appointed Brooke Story as chairman of the board, enhancing governance and leadership.

Financial highlights

  • Q4 2025 R&D expenses were $6.2M, down from $7M year-over-year, reflecting trial completion.

  • Q4 2025 net loss was $8.5M ($0.41/share), unchanged from prior year but with lower per-share loss.

  • Full-year 2025 net loss was $34.2M ($2.09/share), up from $29M ($4.91/share) in 2024.

  • Full-year 2025 R&D expenses rose to $23.8M from $22.8M, driven by trial and regulatory activities.

  • G&A expenses increased to $1.8M in Q4 2025 (from $1M) and $7.2M for the year (from $4.3M), mainly due to non-cash PSU vesting.

Outlook and guidance

  • Rolling NDA submission for D-PLEX100 to begin by end of Q1 2026, with FDA review expected to be shortened to 6 months due to Fast Track and Breakthrough Therapy Designation.

  • Existing cash resources expected to fund operations into the second half of 2026 and through key milestones.

  • Focus remains on U.S. commercialization, with European submission planned after FDA filing.

D-PLEX100 partnership timeline?
Kynatrix GLP-1 program: next development step?
Cash runway beyond H2 2026: funding plan?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next PolyPid earnings date

Logotype for PolyPid Ltd
Q1 202613 May, 2026
PolyPid
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next PolyPid earnings date

Logotype for PolyPid Ltd
Q1 202613 May, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

PolyPid Ltd. is a late-stage biopharmaceutical company focused on enhancing surgical outcomes through innovative drug delivery systems. The company's proprietary PLEX (Polymer-Lipid Encapsulation Matrix) technology is designed to enable localized, prolonged, and controlled release of active pharmaceutical ingredients at the surgical site. This technology aims to optimize therapeutic efficacy and minimize side effects by maintaining a consistent drug presence over an extended period. The company is headquartered in Petach Tikva, Israel, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage